The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Extramedullary hematopoiesis (EMH) in the spleen is a characteristic feature of the chronic myeloproliferative disorders (CMPDs) and various other neoplastic or reactive myeloid conditions. However, the origin of these hematopoietic precursor cells and the molecular mechanisms underlying their development in the spleen is uncertain. The V617F mutation in the Janus Kinase 2 gene (JAK2(V617F)) was recently shown to be frequently and preferentially present in the peripheral blood and bone marrow cells of CMPD patients, and the resulting dysregulation of its downstream targets is important to CMPD pathogenesis. To determine the occurrence and potential role of JAK2(V617F) in splenic EMH cells, we studied splenectomy specimens from 47 patients with significant EMH. JAK2(V617F) was detected by real-time PCR melting curve analysis in 22 specimens, including 11/17 chronic idiopathic myelofibrosis, 7/7 polycythemia vera, 1/1 essential thrombocythemia, 1/3 CMPD unclassifiable, 1/5 chronic myelomonocytic leukemia, 0/5 chronic myelogenous leukemia, 1/3 myelodysplastic syndrome and 0/6 acute myeloblastic leukemia cases, whereas only the JAK2 wild-type allele was detected in the other 25. Nineteen of 20 cases with adequate bone marrow samples available for molecular examination demonstrated concordant JAK2 genotypes. Laser-capture microdissection was then used to enrich the EMH and non-EMH splenic cell fractions, confirming that the mutant alleles specifically originated from the EMH cells. Furthermore, megakaryocytes in the JAK2(V617F)-positive splenectomy specimens expressed higher levels of Bcl-xL, an antiapoptotic protein and downstream target of the JAK2/STAT5 pathway. Thus, JAK2(V617F) is frequently present in splenic EMH cells associated with CMPD, but it is rarely identified in splenic EMH cells associated with other myeloid disorders. Our results indicate that the precursor cells leading to extramedullary hematopoietic expansion in CMPD most likely originate from the transformed bone marrow clone. Also, dysregulation of downstream pathways such as Bcl-xL may be important to CMPD disease pathogenesis in the spleen.
Hsieh
Pin-Pen
PP
Department of Pathology and Laboratory Medicine, The Methodist Hospital and the Methodist Hospital Research Institute, Houston, TX 77030, USA.
Olsen
Randy J
RJ
O'Malley
Dennis P
DP
Konoplev
Sergej N
SN
Hussong
Jerry W
JW
Dunphy
Cherie H
CH
Perkins
Sherrie L
SL
Cheng
Liang
L
Lin
Pei
P
Chang
Chung-Che
CC
D001854:Bone Marrow Cells / Q000737:chemistry / Q000201:enzymology; D002908:Chronic Disease; D006411:Hematopoiesis, Extramedullary / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism; D007834:Lasers; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000201:enzymology / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000201:enzymology / Q000235:genetics; D015477:Leukemia, Myelomonocytic, Chronic / Q000097:blood / Q000201:enzymology / Q000235:genetics; D008533:Megakaryocytes / Q000737:chemistry / Q000201:enzymology; D042282:Microdissection / Q000379:methods; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000201:enzymology / Q000235:genetics; D009196:Myeloproliferative Disorders / Q000097:blood / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism; D011087:Polycythemia Vera / Q000097:blood / Q000201:enzymology / Q000235:genetics; D016133:Polymerase Chain Reaction; D055728:Primary Myelofibrosis / Q000097:blood / Q000201:enzymology / Q000235:genetics; D012189:Retrospective Studies; D013154:Spleen / Q000737:chemistry / Q000201:enzymology; D013920:Thrombocythemia, Essential / Q000097:blood / Q000201:enzymology / Q000235:genetics; D014481:United States; D051020:bcl-X Protein / Q000032:analysis
C494811:BCL2L1 protein, human; D051020:bcl-X Protein; C507924:JAK2 protein, human; D053614:Janus Kinase 2